Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16919622 | 0.92 | CYP2D6 (0.38) | CYP2D6HSP90AA1KDM4ESMN1; SMN2ESR1 | |
| SCHEMBL26774452 | 0.89 | CYP2D6 (0.41) | CYP2D6HSP90AA1KDM4EESR1ESR2 | |
| SCHEMBL10042014 | 0.88 | HSP90AA1 (0.38) | CYP2D6HSP90AA1ESR1ESR2FAAH | |
| SCHEMBL22308557 | 0.86 | NR1I2 (0.40) | CYP2D6KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL26078439 | 0.86 | NR1I2 (0.40) | CYP2D6KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL16402489 | 0.81 | ESR1 (0.36) | CYP2D6HSP90AA1ESR1ESR2FAAH | |
| SCHEMBL23709521 | 0.81 | CYP2D6 (0.42) | CYP2D6HSP90AA1KDM4ELMNAMAPT | |
| SCHEMBL21362869 | 0.80 | CYP2D6 (0.41) | CYP2D6HSP90AA1KDM4ELMNAMAPT | |
| SCHEMBL18660991 | 0.79 | CYP2D6 (0.37) | CYP2D6HSP90AA1LMNAMAPTMAPK1 | |
| SCHEMBL21362944 | 0.79 | CYP2D6 (0.41) | CYP2D6KDM4ESMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| EP-1549624-B1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | SCRIPPS RESEARCH INST (US) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | DHPS, PDXK, NQO1 | CYP2D6 72/4885HSP90AA1 4562/4885KDM4E 669/4885 |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | CYP2D6 1720/4885HSP90AA1 1585/4885KDM4E 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.